Please assess the completion status of the following clinical trial:

Trial Title: ESPB vs FICB for Pain Management Following Total Hip Prosthesis Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ASA classification I-III~* Aged 18-80 years~* Who will be scheduled for total hip prosthesis surgery under spinal anesthesia~Exclusion Criteria:~* Patients who have a history of bleeding diathesis~* Take anticoagulant therapy~* History of chronic pain before surgery~* Known local anesthetics and opioid allergy~* Pregnancy or lactation~* Infection at the site of block~* Patients who do not accept the procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GroupFICB= fascia iliaca compartment block (Type: ACTIVE_COMPARATOR): ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and then for correction of the needle 2 ml saline will be injected deep into the erector spinae muscle fascia. Following confirmation of the correct position of the needle 30 ml 0.25% bupivacaine will be administered for the block.
- Group ESPB = erector spina plan block (Type: ACTIVE_COMPARATOR): FIC block will be performed in the supine position. The linear probe is placed transversely to identify the femoral artery, iliopsoas muscle, and fascia iliaca at the inguinal crease. The probe will be tilted cranially and caudally until optimal images of the fascia iliaca are obtained. Block needle (50 mm, 22G) will be passed through the iliac fascia via the in-plane method. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected.

Based on this trial design, predict the completion outcome and termination type (if applicable).